Investor Presentation

RNS Number : 5766P
e-Therapeutics plc
20 October 2021
 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Investor Presentation

 

 

Oxford, UK, 20 October 2021  - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, is pleased to announce that Ali Mortazavi, CEO, will provide a live presentation relating to the Company's Interim results for the six months ended 31 July 2021 via the Investor Meet Company platform on  26 October 2021 at 4.30 p.m. BST.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00 a.m. the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet e-therapeutics plc via:

https://www.investormeetcompany.com/e-therapeutics-plc/register-investor

Investors who already follow e-therapeutics plc on the Investor Meet Company platform will automatically be invited.

 

 

Enquiries :

 

e-therapeutics plc

Tel: +44 (0)1993 883 125

Ali Mortazavi, CEO

www.etherapeutics.co.uk

Karl Keegan, CFO

 

 

 

 

SP Angel Corporate Finance LLP

 

Tel: +44(0)20 3470 0470

Nominated Adviser and Broker

 

Matthew Johnson/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.  

 

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Our biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology. 

 

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEASENFDKFFFA
UK 100

Latest directors dealings